助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   重度血小板减少症 的翻译结果: 查询用时:0.513秒
图标索引 在分类学科中查询
所有学科
更多类别查询

图标索引 历史查询
 

重度血小板减少症
相关语句
  severe thrombocytopenia
     Conclusion ① The most befitting dose of glucocorticosteroid for treating SLE associated with moderate or severe thrombocytopenia is about deltadehydrocortisone 0 5~1 mg·kg -1 ·d -1 ,and the main side effect of great dose glucocorticosteroid is increasing infection;
     结论 ①激素治疗SLE伴中、重度血小板减少症以相当于泼尼松 0 5~ 1mg·kg- 1 ·d- 1 为宜 ,大剂量激素的主要副作用是增加感染 ;
短句来源
     Methods: Two kinds of dose glucocorticosteroid and glucocorticosteroid allied with vincristine were used respectively in 40 patients with SLE associated with severe thrombocytopenia (BPC<20×109/L). So as to compare their difference of curative effects on thrombocytopenia.
     方法对40例SLE伴重度血小板减少症(血小板<20×109/L)患者分别使用两种不同剂量激素以及激素与长春新碱联用三种方案治疗,比较3组间对血小板减少疗效的差异。
短句来源
     Objective To study the perinatal nursing measures about the puerpera with severe thrombocytopenia.
     目的探讨妊娠合并重度血小板减少症的围产期护理措施。
短句来源
  “重度血小板减少症”译为未确定词的双语例句
     Domestic-made recombinant human interleukin-11 for the treatment of 25 cases of severe thrombopenia induced by chemotherapy
     国产基因重组人白细胞介素-11治疗化疗致重度血小板减少症25例
短句来源
     Objective To observe clinical efficacy of domestic-made recombinant human interleukin-11(rhIL-11)in treatment of severe thrombopenia(TBP) induced by chemotherapy.
     目的观察国产基因重组人白细胞介素-11(rhIL-11)对化疗致重度血小板减少症(TBP)的临床疗效。
短句来源
  相似匹配句对
     Objective To study the perinatal nursing measures about the puerpera with severe thrombocytopenia.
     目的探讨妊娠合并重度血小板减少症的围产期护理措施。
短句来源
     severe: 3, which cannot be suffered.
     3重度,不能忍受。
短句来源
     2. In severe PIH cases, interference delivery rate is higher than natural delivery rate.
     2.在重度PIH。
短句来源
     Drug Induced Thrombocytopenic Syndrome
     药物所致的血小板减少症
短句来源
     THE NURSING FOR THE PATIENTS SUFFERING PLATELET DECREASE
     血小板减少症病人的护理
短句来源
查询“重度血小板减少症”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
为了更好的帮助您理解掌握查询词或其译词在地道英语中的实际用法,我们为您准备了出自英文原文的大量英语例句,供您参考。
  severe thrombocytopenia
A 69-yr-old male with a history of familial hemochromatosis and status after liver transplantation was found to have severe thrombocytopenia (platelet count of 8000/μL).
      
We report a case of severe thrombocytopenia after Irinotecan, suggesting an immune mechanism, in a 53-year-old patient.
      
Neuroleptic Malignant Syndrome and Severe Thrombocytopenia: Case Report and Literature Review
      
10 patients with aplastic anemia and severe thrombocytopenia strongly immunized by previous blood transfusions were transfused with platelets from cross-match negative related or unrelated donors.
      
Additionally slight leucocytopenia (2/1) and thrombocytopenia (6/2) were observed; abnormal bleeding was only seen in one patient with severe thrombocytopenia.
      
更多          


Objective To study morphological characteristics of placenta in severe pregnancy induced hypertension (SPIH) and its relationship to pregnant outcome. Methods Morphological changes were observed by light microscopy; Blood biochemical analyses were used to predispose pregnant outcome. Results Difference in pathological changes of placental bed between normal term pregnancy (NTP) and SPIH groups was significant: the placental weight, proliferation of cytotrophoblasts, numbers of the placental villi with syncytial...

Objective To study morphological characteristics of placenta in severe pregnancy induced hypertension (SPIH) and its relationship to pregnant outcome. Methods Morphological changes were observed by light microscopy; Blood biochemical analyses were used to predispose pregnant outcome. Results Difference in pathological changes of placental bed between normal term pregnancy (NTP) and SPIH groups was significant: the placental weight, proliferation of cytotrophoblasts, numbers of the placental villi with syncytial knots, thickness of basal lamina, fibrinoid necrosis and deposition of matrix, stromal edema and fibrosis of villi, the vascular numbers of villi, stasis; lack of physiologic changes in decidual spiral arteries. Clinical examination showed that the rate of anemia, thrombocytopenia, blood concentration, hypoproteinemia, ascites, eye ground artery spasm in SPIH were higher in NIT. Conclusions Pathological changes of placenta play important roles in development of SPIH, and the pathological changes are paralleled with the severity of the disease.

目的 探讨重度妊娠高血压综合征 (妊高征 )患者子宫胎盘病理变化及其对孕产妇和围产儿结局的影响。方法 选择正常晚孕妇女 (对照组 )和重度妊高征患者 (观察组 )各 117例 ,常规HE染色观察胎盘形态学变化 ,并对两组孕妇进行血液分析、生化检查及肝肾功能检查。结果 观察组胎盘重量明显减轻 ,细胞滋养细胞增殖 ,合体滋养细胞结节增多 ,基底膜增厚 ,基质纤维素样坏死 ,绒毛间隙水肿 ,绒毛内血管数目减少、淤血严重等 ,蜕膜内血管生理性改变消失 ,与对照组上述各指标比较 ,差异均有极显著性 (P <0 0 1) ;观察组合并严重贫血、重度血小板减少症、血液高粘度、低蛋白血症、大量腹水、眼底动脉痉挛性改变等多于对照组 ,差异具有极显著性 (P <0 0 1)。结论 重度妊高征患者胎盘形态学病理变化明显 ,且与病情严重程度呈平行关系。

s A randomized, selfcross-over and placebo-controlled clinical trial has been taken to evaluated the curative efficacy of rhIL-11(Mega) for thrombocytopenia in 29 cancer patients with severe myelosuppression induced by chemotherapy. Twenty-five μg/kg of Mega or placebo was administered subcutaneously once daily starting 24 hours after the completion of chemotherapy, and continuing for 7 to 14 days or until the platelet count reached 300×10 9/L. The results from those in 118 cases performed phase Ⅱ clinical...

s A randomized, selfcross-over and placebo-controlled clinical trial has been taken to evaluated the curative efficacy of rhIL-11(Mega) for thrombocytopenia in 29 cancer patients with severe myelosuppression induced by chemotherapy. Twenty-five μg/kg of Mega or placebo was administered subcutaneously once daily starting 24 hours after the completion of chemotherapy, and continuing for 7 to 14 days or until the platelet count reached 300×10 9/L. The results from those in 118 cases performed phase Ⅱ clinical trial, showed that there were 29 cases with platelet count less than 50×10 9/L in placebo cycle, but there was only 1 case in Mega cycle. The percentage of the patients with platelet count less than 50×10 9/L in placebo cycle of placebo+Mega group was higher than that of Mega+placebo group. The nadir and platelet counts on day 21 after chemotherapy in Mega cycle were 2.04 and 1.43 times more than those in placebo cycle, respectively. The data show that Mega had significant thrombopoietic activity with a long lasting oction for the patients experienced severe myelosuppression. It significantly increases the likelyhood of avoiding thrombocytopenia in cancer patients undergoing chemotherapy and shortens the duration of thrombocytopenia.

观察国产重组人白细胞介素 11(rhIL 11,迈格尔 )对重度骨髓抑制病人的血小板恢复作用。采用随机双盲自身交叉对照方法进行研究。在化疗药物给药结束后 2 4小时开始给迈格尔 2 5μg kg ,皮下注射 ,每日 1次 ,连续用药 7- 14天或至血小板计数≥ 30 0× 10 9 L。对化疗后血小板值低于 5 0× 10 9 L(重度骨髓抑制 )的病例进行统计分析研究。结果表明 ,临床Ⅱ期试用的 118例可评价病例中 ,安慰剂对照周期血小板值低于 5 0× 10 9 L的例数为 2 9例 ,占 2 4 .5 8%,而迈格尔治疗周期仅 1例血小板值低于 5 0× 10 9 L ,占 0 .84 %;先给安慰剂后给迈格尔组安慰剂对照周期血小板值低于 5 0× 10 9 L的比例高于先给迈格尔后给安慰剂组 ,两者分别为 32 .2 0 %和 16 .95 %;迈格尔治疗周期血小板最低值和化疗第 2 1天血小板值分别是安慰剂对照周期的 3.0 4倍和 2 .4 3倍。本试验结果说明 ,迈格尔可促进重度骨髓抑制病人的血小板恢复 ,减少肿瘤病人化疗后重度血小板减少症的发生 ,缩短重度血小板减少症$...

观察国产重组人白细胞介素 11(rhIL 11,迈格尔 )对重度骨髓抑制病人的血小板恢复作用。采用随机双盲自身交叉对照方法进行研究。在化疗药物给药结束后 2 4小时开始给迈格尔 2 5μg kg ,皮下注射 ,每日 1次 ,连续用药 7- 14天或至血小板计数≥ 30 0× 10 9 L。对化疗后血小板值低于 5 0× 10 9 L(重度骨髓抑制 )的病例进行统计分析研究。结果表明 ,临床Ⅱ期试用的 118例可评价病例中 ,安慰剂对照周期血小板值低于 5 0× 10 9 L的例数为 2 9例 ,占 2 4 .5 8%,而迈格尔治疗周期仅 1例血小板值低于 5 0× 10 9 L ,占 0 .84 %;先给安慰剂后给迈格尔组安慰剂对照周期血小板值低于 5 0× 10 9 L的比例高于先给迈格尔后给安慰剂组 ,两者分别为 32 .2 0 %和 16 .95 %;迈格尔治疗周期血小板最低值和化疗第 2 1天血小板值分别是安慰剂对照周期的 3.0 4倍和 2 .4 3倍。本试验结果说明 ,迈格尔可促进重度骨髓抑制病人的血小板恢复 ,减少肿瘤病人化疗后重度血小板减少症的发生 ,缩短重度血小板减少症的持续时间 ,且具有一定的后续效应。

Objective To study the short and long term curative effects of glucocorticosteroid on systemic lupus erythematosus (SLE) associated with thrombocytopenia,and analyze their related factors.Methods Retrospective follow up and analysis were done in 82 patients whose final diagnosis was SLE associated with moderate or severe thrombocytopenia (BPC<50×10 9/L) in 1999 and 2001.The study items included the short and long term curative effects on thrombocytopenia,the activity of the disease,the degree of bone...

Objective To study the short and long term curative effects of glucocorticosteroid on systemic lupus erythematosus (SLE) associated with thrombocytopenia,and analyze their related factors.Methods Retrospective follow up and analysis were done in 82 patients whose final diagnosis was SLE associated with moderate or severe thrombocytopenia (BPC<50×10 9/L) in 1999 and 2001.The study items included the short and long term curative effects on thrombocytopenia,the activity of the disease,the degree of bone marrow hyperplasia,and the relationship among the related factors at the level of platelet antibody (PAIg) and anti cardiolipin antibody (ACLA).Results There was no significant difference between the short (4~8 weeks) and long term (12~24 weeks) curative effects in the group of middle and large doses (deltadehydrocortisone 0 5~1 mg·kg -1 ·d -1 ) and the group of very large dose (deltadehydrocortisone≥2 mg·kg -1 ·d -1 ) ( P <0 05).The whole effective rate for patients with active disease was higher than those with low active disease ( P <0 01).The whole effective rate for patients with active bone marrow hyperplasia is higher than those with little bone marrow hyperplasia ( P <0 05).There was no significant difference in effective rate between PAIg positive group and PAIg negative group ( P >0 05).There was no significant difference in effective rate between ACLA positive group and ACLA negative group too ( P >0 05).Conclusion ① The most befitting dose of glucocorticosteroid for treating SLE associated with moderate or severe thrombocytopenia is about deltadehydrocortisone 0 5~1 mg·kg -1 ·d -1 ,and the main side effect of great dose glucocorticosteroid is increasing infection;② The patients with active disease and those with active bone marrow hyperplasia have good response to the treatment.

目的 研究糖皮质激素治疗系统性红斑狼疮 (SLE)伴血小板减少症的近远期疗效 ,分析影响疗效的相关因素。方法 对 1999— 2 0 0 1年确诊为SLE伴中、重度血小板减少 (血小板 <5 0× 10 9 L) 82例患者进行回顾性分析及随访 ,研究糖皮质激素治疗血小板减少症的近远期疗效及与疾病活动性、骨髓增生程度、血小板抗体 (PAIg)及抗心磷脂抗体 (ACLA)水平因素的相关性。 结果 中、大剂量组 (泼尼松 0 5~ 1mg·kg- 1 ·d- 1 )与超大剂量激素组 (泼尼松≥ 2mg·kg- 1 ·d- 1 )其近期 (4~ 8周 )疗效及远期 (12~ 2 4周 )疗效差异均无显著性 (P >0 0 5 )。具有高活动性组的治疗总有效率优于低活动性组 (P <0 0 1)。骨髓增生活跃组治疗总有效率优于增生低下组的有效率 (P <0 0 5 )。血小板抗体阳性组与阴性组治疗的有效率差异无显著性 (P >0 0 5 )。ACLA阳性组与阴性组的治疗总有效率差异无显著性 (P >0 0 5 )。结论 ①激素治疗SLE伴中、重度血小板减少症以相当于泼尼松 0 5~ 1mg·...

目的 研究糖皮质激素治疗系统性红斑狼疮 (SLE)伴血小板减少症的近远期疗效 ,分析影响疗效的相关因素。方法 对 1999— 2 0 0 1年确诊为SLE伴中、重度血小板减少 (血小板 <5 0× 10 9 L) 82例患者进行回顾性分析及随访 ,研究糖皮质激素治疗血小板减少症的近远期疗效及与疾病活动性、骨髓增生程度、血小板抗体 (PAIg)及抗心磷脂抗体 (ACLA)水平因素的相关性。 结果 中、大剂量组 (泼尼松 0 5~ 1mg·kg- 1 ·d- 1 )与超大剂量激素组 (泼尼松≥ 2mg·kg- 1 ·d- 1 )其近期 (4~ 8周 )疗效及远期 (12~ 2 4周 )疗效差异均无显著性 (P >0 0 5 )。具有高活动性组的治疗总有效率优于低活动性组 (P <0 0 1)。骨髓增生活跃组治疗总有效率优于增生低下组的有效率 (P <0 0 5 )。血小板抗体阳性组与阴性组治疗的有效率差异无显著性 (P >0 0 5 )。ACLA阳性组与阴性组的治疗总有效率差异无显著性 (P >0 0 5 )。结论 ①激素治疗SLE伴中、重度血小板减少症以相当于泼尼松 0 5~ 1mg·kg- 1 ·d- 1 为宜 ,大剂量激素的主要副作用是增加感染 ;②活动性高及骨髓增生度好的患者对治疗的反应好。

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关重度血小板减少症的内容
在知识搜索中查有关重度血小板减少症的内容
在数字搜索中查有关重度血小板减少症的内容
在概念知识元中查有关重度血小板减少症的内容
在学术趋势中查有关重度血小板减少症的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社